Incretin signalling: GLP-1 and GIP
GLP-1 and GIP are incretin hormones involved in glucose-dependent metabolic signalling. Tirzepatide acts at both receptors, while semaglutide acts at the GLP-1 receptor. Specific prescription medicines containing these ingredients have regulatory approvals for defined uses.
Retatrutide adds a glucagon target
Retatrutide is a triple agonist at GLP-1, GIP and glucagon receptors. Clinical research has investigated its effects on body-weight regulation and metabolic outcomes. It remains an investigational compound, distinct from an approved prescription product.
Amylin-related research
Cagrilintide is a long-acting amylin-related peptide being studied in appetite and metabolic pathways, including combinations with GLP-1 receptor agonists. It remains investigational. It is discussed here as scientific context, rather than as an Aurelis stock listing.
Compare targets, not promises
Receptor profiles help describe the scientific questions being studied. They do not alone predict an individual’s outcome or establish the quality and performance of a separately supplied research material.
Our catalogue includes retatrutide and tirzepatide research enquiries with listed content and product-specific context. Semaglutide and cagrilintide are included in this article for comparison only.
Sources
- Published research · PubMed 1
- Official prescribing information · FDA 2
- Published research · PubMed 3
- Regulatory source · FDA 4
Scientific context reviewed 25 September 2026.